Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma Meeting Abstract
| Authors: | Locke, F. L.; Miklos, D. B.; Jacobson, C.; Perales, M. A.; Kersten, M. J.; Oluwole, O. O.; Ghobadi, A.; Rapoport, A. P.; McGuirk, J. P.; Pagel, J. M.; Muñoz, J.; Farooq, U.; Van Meerten, T.; Reagan, P. M.; Sureda, A.; Flinn, I. W.; Vandenberghe, P.; Song, K.; Dickinson, M.; Minnema, M. C.; Riedell, P. A.; Leslie, L. A.; Chaganti, S.; Yang, Y.; Filosto, S.; Schupp, M.; To, C.; Cheng, P.; Gordon, L. I.; Westin, J. R. |
| Abstract Title: | Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398800003 |
| DOI: | 10.1182/blood-2021-148039 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2 -- Hybrid meeting, also took place online -- Source: Wos |
